Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group
Jason N. BermanDepartment of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, CanadaRobert B. GerbingChildren's Oncology Group, Arcadia, CA, USATodd A. AlonzoChildren's Oncology Group, Arcadia, CA, USAPhoenix A. HoClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USAKristen L. MillerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USACraig A. HurwitzReata Pharmaceuticals, Dallas, TX, USANyla A. HeeremaDepartment of Pathology, The Ohio State University, Columbus, OH, USABetsy HirschDepartment of Laboratory Medicine and Pathology, University of Minnesota Cancer Center, Minneapolis, MN, USASusana C. RaimondiDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USABeverly J. LangeDepartment of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USAJanet FranklinAmgen Pharmaceuticals, Thousand Oaks, CA, USAAlan S. GamisDivision of Hematology/Oncology/Bone Marrow Transplantation, Children′s Mercy Hospital & Clinics, Kansas City, MO, USASoheil MeshinchiClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
2011en
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba